| Year |
Citation |
Score |
| 2023 |
Wu C, Spector SA, Theodoropoulos G, Nguyen DJM, Kim EY, Garcia A, Savaraj N, Lim DC, Paul A, Feun LG, Bickerdike M, Wangpaichitr M. Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer. Cancer & Metabolism. 11: 7. PMID 37226257 DOI: 10.1186/s40170-023-00307-1 |
0.406 |
|
| 2021 |
Wu C, You M, Nguyen D, Wangpaichitr M, Li YY, Feun LG, Kuo MT, Savaraj N. Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. International Journal of Molecular Sciences. 22. PMID 34299249 DOI: 10.3390/ijms22147628 |
0.393 |
|
| 2019 |
Nguyen DJ, Theodoropoulos G, Li YY, Wu C, Sha W, Feun LG, Lampidis TJ, Savaraj N, Wangpaichitr M. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular Cancer Research : McR. PMID 31628200 DOI: 10.1158/1541-7786.Mcr-19-0239 |
0.733 |
|
| 2019 |
Savaraj N, Li Y, Wu C, Wangpaichitr M, Spector S, Sentome M, Feun LG. Abstract 4747: Surviving skills in melanoma cells: An important consideration to both targeted and immunological approach in the treatment of melanoma Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4747 |
0.335 |
|
| 2019 |
Wangpaichitr M, Nguyen DJ, Li Y, Wu C, Feun LG, Savaraj N. Abstract 4361: Kynurenine - Aryl hydrocarbon receptor axis: A crucial modulator of immunometabolism in cisplatin resistant lung cancer Cancer Research. 79: 4361-4361. DOI: 10.1158/1538-7445.Sabcs18-4361 |
0.516 |
|
| 2018 |
Wangpaichitr M, Wu C, Nguyen DJ, Li Y, Feun LG, Savaraj N. Abstract 5478: Targeting kynurenine pathway for the treatment of cisplatin-resistant lung cancer Cancer Research. 78: 5478-5478. DOI: 10.1158/1538-7445.Am2018-5478 |
0.497 |
|
| 2018 |
Wu C, Li Y, Wangpaichitr M, Feun LG, Kuo MT, Savaraj N. Abstract 3642: Relationship of argininosuccinate synthetase (ASS) and PD-L1 expression in arginine enriched or depleted environment in melanoma Cancer Research. 78: 3642-3642. DOI: 10.1158/1538-7445.Am2018-3642 |
0.384 |
|
| 2017 |
Li YY, Wu C, Shah SS, Chen SM, Wangpaichitr M, Kuo MT, Feun LG, Han X, Suarez M, Prince J, Savaraj N. Degradation of AMPK-α1 Sensitizes BRAF Inhibitor-Resistant Melanoma Cells to Arginine Deprivation. Molecular Oncology. PMID 29094484 DOI: 10.1002/1878-0261.12151 |
0.546 |
|
| 2017 |
Wangpaichitr M, Kandemir H, Li YY, Wu C, Nguyen D, Feun LG, Kuo MT, Savaraj N. Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer. Cell & Developmental Biology. 6. PMID 28819582 DOI: 10.4172/2168-9296.1000183 |
0.329 |
|
| 2017 |
Li YY, Feun LG, Thongkum A, Tu CH, Chen SM, Wangpaichitr M, Wu C, Kuo MT, Savaraj N. Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy. International Journal of Molecular Sciences. 18. PMID 28629173 DOI: 10.3390/Ijms18061297 |
0.43 |
|
| 2017 |
Thongkum A, Wu C, Li YY, Wangpaichitr M, Navasumrit P, Parnlob V, Sricharunrat T, Bhudhisawasdi V, Ruchirawat M, Savaraj N. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. International Journal of Molecular Sciences. 18. PMID 28587170 DOI: 10.3390/Ijms18061175 |
0.434 |
|
| 2017 |
Wangpaichitr M, Wu C, Li YY, Nguyen DJM, Kandemir H, Shah S, Chen S, Feun LG, Prince JS, Kuo MT, Savaraj N. Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer. Oncotarget. PMID 28525376 DOI: 10.18632/Oncotarget.17568 |
0.543 |
|
| 2017 |
Savaraj N, Chen S, Wu C, Li Y, Wangpaichitr M, Benveniste R, Feun LG. The role of procollagen alpha 1 type 1 (Col1A1) on invasion and cellular signaling in glioma cells. Journal of Clinical Oncology. 35: e23165-e23165. DOI: 10.1200/Jco.2017.35.15_Suppl.E23165 |
0.41 |
|
| 2017 |
Wangpaichitr M, Wu C, Li YY, Feun LG, Kuo MT, Savaraj N. Abstract 4404: Novel approach to circumvent cisplatin resistant lung cancer by targeting metabolism Cancer Research. 77: 4404-4404. DOI: 10.1158/1538-7445.Am2017-4404 |
0.405 |
|
| 2016 |
Long Y, Tsai WB, Chang JT, Estecio M, Wangpaichitr M, Savaraj N, Feun LG, Chen HH, Kuo MT. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Oncotarget. PMID 27765932 DOI: 10.18632/Oncotarget.12308 |
0.358 |
|
| 2016 |
Li YY, Wu C, Chen SM, Shah SS, Wangpaichitr M, Feun LG, Kuo MT, Suarez M, Prince J, Savaraj N. BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma. Oncotarget. PMID 26771234 DOI: 10.18632/Oncotarget.6882 |
0.549 |
|
| 2016 |
Chen S, Wu C, Li Y, Wangpaichitr M, Benveniste RJ, Turkson J, Savaraj N, Feun LG. Abstract 3712: The relationship of Procollagen alpha 1 type 1 (Col1A1) / DDR2 signaling in malignant glioma and sensitivity to STAT 3/5 inhibitor Cancer Research. 76: 3712-3712. DOI: 10.1158/1538-7445.Am2016-3712 |
0.525 |
|
| 2016 |
Li Y, Wu C, Shah S, Chen S, Wangpaichitr M, Feun L, Kuo M, Suarez M, Savaraj N. Abstract 2671: BRAF inhibitor resistance reprograms metabolic and survival pathways to sensitize melanoma cells to arginine deprivation Cancer Research. 76: 2671-2671. DOI: 10.1158/1538-7445.Am2016-2671 |
0.576 |
|
| 2016 |
Wangpaichitr M, Wu C, Li YY, Shah S, Chen S, Dinh V, Kuo MT, Feun LG, Savaraj N. Abstract 1038: Exploiting ROS and metabolic differences to selectively killing cisplatin resistant lung cancer Cancer Research. 76: 1038-1038. DOI: 10.1158/1538-7445.Am2016-1038 |
0.528 |
|
| 2015 |
Savaraj N, Wu C, Li YY, Wangpaichitr M, You M, Bomalaski J, He W, Kuo MT, Feun LG. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin. Oncotarget. 6: 6295-309. PMID 25749046 DOI: 10.18632/Oncotarget.3370 |
0.486 |
|
| 2015 |
Chen S, Wu C, Li YY, Wangpaichitr M, Feun LG, Benveniste R, Dinh V, Savaraj N. Abstract 43: The role of discoidin domain receptor 2 (DDR2) and its relationship with procollagen alpha 1 type 1(Col1A1) in malignant glioma Cancer Research. 75: 43-43. DOI: 10.1158/1538-7445.Am2015-43 |
0.475 |
|
| 2015 |
Li Y, Savaraj N, Wu C, Chen S, Wangpaichitr M, Kuo MT, Feun LG. Abstract 2900: Biochemical alterations in BRAF inhibitor (BRAFi) resistant melanoma cells increase their vulnerability to arginine deprivation Cancer Research. 75: 2900-2900. DOI: 10.1158/1538-7445.Am2015-2900 |
0.552 |
|
| 2015 |
Wangpaichitr M, Wu C, Nguyen DM, You M, Li YY, Chen S, Feun LG, Savaraj N. Abstract 1206: Cisplatin resistant non small cell lung cancer is sensitive to arginine deprivation therapy Cancer Research. 75: 1206-1206. DOI: 10.1158/1538-7445.Am2015-1206 |
0.555 |
|
| 2014 |
Wangpaichitr M, Wu C, Bigford G, Theodoropoulos G, You M, Li YY, Verona-Santos J, Feun LG, Nguyen DM, Savaraj N. Combination of arginine deprivation with TRAIL treatment as a targeted-therapy for mesothelioma. Anticancer Research. 34: 6991-9. PMID 25503125 |
0.359 |
|
| 2014 |
Chen S, Wu C, You M, Tran M, Wangpaichitr M, Li YY, Benveniste RJ, Kuo MT, Savaraj N, Feun LG. Abstract 4192: Exploiting discoidin domain receptor (DDR) and collagen signaling as a new approach to treat human malignant gliomas Cancer Research. 74: 4192-4192. DOI: 10.1158/1538-7445.Am2014-4192 |
0.451 |
|
| 2014 |
Li Y, Wu C, Chen S, Wangpaichitr M, You M, Spector S, Feun LG, Kuo MT, Savaraj N. Abstract 3701: BRAF inhibitor (vemurafenib) resistance confers sensitivity to arginine deprivation in melanoma Cancer Research. 74: 3701-3701. DOI: 10.1158/1538-7445.Am2014-3701 |
0.563 |
|
| 2014 |
You M, Wangpaichitr M, Nguyen JD, Chapman JR, Cioffi-Lavina M, Savaraj N, Nguyen DM. Abstract 1435: Exploiting obligate arginine auxotrophy in tumor cells lacking arginino-succinate synthetase (ASS) expression to develop targeted molecular therapy for non-small cell lung cancer (NSCLC) Cancer Research. 74: 1435-1435. DOI: 10.1158/1538-7445.Am2014-1435 |
0.536 |
|
| 2014 |
Wangpaichitr M, Wu C, Li YY, Chen S, You M, Dinh V, Feun LG, Kuo MT, Savaraj N. Abstract 1428: Targeting metabolic alteration in cisplatin-resistant lung cancer Cancer Research. 74: 1428-1428. DOI: 10.1158/1538-7445.Am2014-1428 |
0.493 |
|
| 2014 |
Chen S, Wu C, Li Y, Feun L, Wangpaichitr M, Benveniste RJ, Savaraj N. CS-03 * UTILIZING COLLAGEN AND DISCOIDIN DOMAIN RECEPTOR SIGNALING AS A NEWTHERAPEUTIC STRATEGY IN HUMAN MALIGNANT GLIOMA Neuro-Oncology. 16: v51-v51. DOI: 10.1093/Neuonc/Nou242.3 |
0.416 |
|
| 2013 |
Long Y, Tsai WB, Wangpaichitr M, Tsukamoto T, Savaraj N, Feun LG, Kuo MT. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Molecular Cancer Therapeutics. 12: 2581-90. PMID 23979920 DOI: 10.1158/1535-7163.Mct-13-0302 |
0.535 |
|
| 2013 |
You M, Savaraj N, Kuo MT, Wangpaichitr M, Varona-Santos J, Wu C, Nguyen DM, Feun L. TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Molecular and Cellular Biochemistry. 374: 181-90. PMID 23180246 DOI: 10.1007/S11010-012-1518-1 |
0.459 |
|
| 2013 |
Wangpaichitr M, Theodoropoulos G, Wu C, Poochareon N, Li YY, You M, Kuo MT, Feun LG, Savaraj N. Abstract 961: Selectively kill cisplatin resistant lung cancer cells by exploiting ROS and metabolic differences. Cancer Research. 73: 961-961. DOI: 10.1158/1538-7445.Am2013-961 |
0.564 |
|
| 2012 |
Wangpaichitr M, Sullivan EJ, Theodoropoulos G, Wu C, You M, Feun LG, Lampidis TJ, Kuo MT, Savaraj N. The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Molecular Cancer Therapeutics. 11: 604-15. PMID 22248473 DOI: 10.1158/1535-7163.Mct-11-0599 |
0.75 |
|
| 2012 |
Wangpaichitr M, Theodoropoulos G, Wu C, You M, Feun LG, Kuo MT, Lampidis TJ, Savaraj N. Abstract 1138: The emerging role of thioredoxin-1 on ROS and metabolic reprogramming in cisplatin resistant lung cancer Cancer Research. 72: 1138-1138. DOI: 10.1158/1538-7445.Am2012-1138 |
0.733 |
|
| 2011 |
Dinh V, You M, Savaraj N, Wu C, Kuo MT, Wangpaichitr M, Feun LG. Determining argininosuccinate synthetase (ASS) expression in patients with melanoma treated with arginine depleting therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10627. PMID 28022879 DOI: 10.1200/Jco.2011.29.15_Suppl.10627 |
0.393 |
|
| 2011 |
Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Liu X, Savaraj N, Lampidis TJ. 2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemotherapy and Pharmacology. 67: 899-910. PMID 20593179 DOI: 10.1007/S00280-010-1391-0 |
0.768 |
|
| 2011 |
Santos JV, You M, Wangpaichitr M, Savaraj N, Nguyen DM. Abstract LB-222: Identifying cFLIP as a marker and also a potentially “druggable” target of SAHA+TRAIL (TNF-Related Apoptosis Inducing Ligand), cytotoxicity in malignant pleural mesothelioma (MPM) Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-222 |
0.555 |
|
| 2011 |
You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Feun L. Abstract 4096: TRAIL enhances cytotoxicity of arginine depletion therapy in argininosuccinate synthetase-negative melanoma cells through interruption of autophagy via activation of caspases Cancer Research. 71: 4096-4096. DOI: 10.1158/1538-7445.Am2011-4096 |
0.471 |
|
| 2011 |
Sullivan EJ, Kurtoglu M, Wangpaichitr M, Savaraj N, Lampidis T. Abstract 4087: Metabolic changes associated with acquired cisplatin resistance Cellular and Molecular Biology. 71: 4087-4087. DOI: 10.1158/1538-7445.Am2011-4087 |
0.747 |
|
| 2011 |
Wangpaichitr M, Wu C, You M, Feun LG, Kuo MT, Dinh V, Savaraj N. Abstract 1692: Downregulation of thioredoxin-1 confers resistance to cisplatin and sensitivity to the ROS generating agent elesclomol Cancer Research. 71: 1692-1692. DOI: 10.1158/1538-7445.Am2011-1692 |
0.515 |
|
| 2010 |
Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Current Molecular Medicine. 10: 405-12. PMID 20459375 DOI: 10.2174/156652410791316995 |
0.486 |
|
| 2010 |
You M, Savaraj N, Wangpaichitr M, Wu C, Kuo MT, Varona-Santos J, Nguyen DM, Feun L. The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochemical and Biophysical Research Communications. 394: 760-6. PMID 20227389 DOI: 10.1016/J.Bbrc.2010.03.066 |
0.489 |
|
| 2010 |
Feun LG, You M, Wu C, Wangpaichitr M, Kuo MT, Marini A, Jungbluth A, Savaraj N. Final results of phase II trial of pegylated arginine deiminase (ADI-PEG20) in metastatic melanoma (MM). Journal of Clinical Oncology. 28: 8528-8528. DOI: 10.1200/Jco.2010.28.15_Suppl.8528 |
0.354 |
|
| 2010 |
You M, Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Dinh V, Feun LG. Abstract 61: Enhancing arginine deprivation therapy in melanoma by combining with cisplatin Cancer Research. 70: 61-61. DOI: 10.1158/1538-7445.Am10-61 |
0.529 |
|
| 2010 |
Xi H, Kurtoglu M, Liu H, Wangpaichitr M, You M, Savaraj N, Lampidis TJ. Abstract 4840: 2-Deoxy-D-glucose induces autophagy through endoplasmic reticulum stress rather than by lowering ATP Cancer Research. 70: 4840-4840. DOI: 10.1158/1538-7445.Am10-4840 |
0.791 |
|
| 2010 |
Wangpaichitr M, Wu C, Kuo Mt, You M, Dinh V, Feun L, Savaraj N. Abstract 4525: Targeting ROS to kill cisplatin-resistant cells Cancer Research. 70: 4525-4525. DOI: 10.1158/1538-7445.Am10-4525 |
0.559 |
|
| 2010 |
Santos JV, Vara A, Thomas C, Wangpaichitr M, You M, Savaraj N, Nguyen DM. Abstract 3489: Profound cytotoxicity of the histone deacetylase inhibitor SAHA (Suberoylanilide Hydroxamic Acid) and TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) combination in malignant pleural mesothelioma Cancer Research. 70: 3489-3489. DOI: 10.1158/1538-7445.Am10-3489 |
0.476 |
|
| 2009 |
Wangpaichitr M, Wu C, You M, Maher JC, Dinh V, Feun LG, Savaraj N. N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers. 1: 23-38. PMID 20535236 DOI: 10.3390/Cancers1010023 |
0.793 |
|
| 2008 |
Bastos BR, Wu C, Wangpaichitr M, Feun LG, Robles C, Savaraj N. Overcoming cisplatin resistance with mTOR inhibition in small cell lung cancer: A phase I-II trial design. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14673. PMID 27949468 DOI: 10.1200/Jco.2008.26.15_Suppl.14673 |
0.538 |
|
| 2008 |
Savaraj N, You M, Wu C, Marini A, Kuo MT, Wangpaichitr M, Bomalaski J, Feun LG. Arginine (Arg) deprivation for the treatment of advanced melanoma: Clinical results/correlation with argininosuccinate synthetase (ASS) expression. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 20019. PMID 27947820 DOI: 10.1200/Jco.2008.26.15_Suppl.20019 |
0.415 |
|
| 2008 |
Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T, Savaraj N. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. European Journal of Pharmacology. 591: 124-7. PMID 18585380 DOI: 10.1016/J.Ejphar.2008.06.028 |
0.733 |
|
| 2008 |
Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Molecular Cancer Therapeutics. 7: 1506-13. PMID 18566221 DOI: 10.1158/1535-7163.Mct-07-2334 |
0.763 |
|
| 2008 |
Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N. Arginine deprivation as a targeted therapy for cancer. Current Pharmaceutical Design. 14: 1049-57. PMID 18473854 DOI: 10.2174/138161208784246199 |
0.487 |
|
| 2007 |
Savaraj N, Wu C, Kuo MT, You M, Wangpaichitr M, Robles C, Spector S, Feun L. The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights. 2: 119-28. PMID 21901069 DOI: 10.4137/Dti.S0 |
0.505 |
|
| 2007 |
Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 6: 3049-58. PMID 18025288 DOI: 10.1158/1535-7163.Mct-07-0310 |
0.76 |
|
| 2007 |
Maher JC, Wangpaichitr M, Savaraj N, Kurtoglu M, Lampidis TJ. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Molecular Cancer Therapeutics. 6: 732-41. PMID 17308069 DOI: 10.1158/1535-7163.Mct-06-0407 |
0.767 |
|
| 2005 |
Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Molecular Cancer. 4: 25. PMID 16033649 DOI: 10.1186/1476-4598-4-25 |
0.716 |
|
| 2005 |
Savaraj N, Wei Y, Unate H, Liu PM, Wu CJ, Wangpaichitr M, Xia D, Xu HJ, Hu SX, Tien Kuo M. Redox regulation of matrix metalloproteinase gene family in small cell lung cancer cells. Free Radical Research. 39: 373-81. PMID 16032782 DOI: 10.1080/10715760400029694 |
0.342 |
|
| 2003 |
Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. International Journal of Oncology. 23: 173-9. PMID 12792791 |
0.701 |
|
| 2003 |
Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. International Journal of Oncology. 23: 173-179. DOI: 10.3892/Ijo.23.1.173 |
0.721 |
|
| 2002 |
Wangpaichitr M, Landy H, Wu CJ, Feun LG, Xu R, Xu J, Savaraj N. Procollagen-Like Protein as a Molecular Target in the Treatment of Primary Brain Tumor. Thescientificworldjournal. 2: 125-126. PMID 29973834 DOI: 10.1100/Tsw.2002.59 |
0.337 |
|
| Show low-probability matches. |